pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

834 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1612Endpoints1263Fierce Biotech591BioSpace589BioPharma Dive476raps199onclive165fda recalls105fda medwatch
therapy area
allOncology11022Rare Disease2811Immunology2578Cardiology2332Pulmonology1942Hematology1915Vaccines1666Psychiatry & CNS1119
  • UCB to buy antibody maker targeting autoimmune diseases
    UCB announced it will acquire a company that develops antibody treatments for autoimmune disorders. The deal expands UCB’s pipeline in a therapeutic area where it seeks to strengthen its market pos…
    STAT · 5mo agoDealNeutral↗ source
  • Two drugmakers petition Supreme Court to reinstate mail-order access to abortion pill mifepristone
    Two drugmakers, Danco Laboratories and GenBioPro, have asked the U.S. Supreme Court to restore mail-order distribution of mifepristone, the abortion pill. The request follows a recent appellate co…
    STAT · 5mo agoRegulatoryNeutral↗ source
← prev
page 33 of 34
next →
95
globenewswire health73
fda press55
Ophthalmology884
Endocrinology & Metabolism703
Pain678
Nephrology676
  • New study shows AI tools in emergency rooms are being overhyped, experts caution
    A recent analysis of artificial‑intelligence applications in emergency departments concluded that the technology’s impact is far more modest than many headlines suggest. The authors warned that exp…
    STAT · 5mo agoNegative↗ source
  • Study finds fatherhood may lower early mortality, calls for more focus on paternal deaths
    Researchers published a letter in JAMA Pediatrics calling for greater study of paternal deaths, noting that being a father may lower early mortality. The authors cite a pilot study from Georgia th…
    STAT · 5mo agoNeutral↗ source
  • Bristol Myers shows modest revenue rise, Biogen beats forecasts, Regeneron outlook remains uncertain
    BioPharma Dive highlighted the latest quarterly earnings from three major biotech firms, noting how investors are interpreting the results. Bristol Myers Squibb reported $11.5 billion in revenue f…
    BioPharma Dive · 5mo agoEarningsNeutral↗ source
  • Ailux appoints former AstraZeneca executive Maria Belvisi as chief scientific officer
    Ailux announced the hiring of Maria Belvisi as its new chief scientific officer. Belvisi comes from AstraZeneca where she served as senior vice president of research and development for respirator…
    STAT · 5mo agoPositive↗ source
  • FDA finds low levels of PFAS in most U.S. baby formulas, says supply remains largely safe
    The FDA recently tested 312 infant formula samples from 16 brands and released its findings. The agency detected five types of PFAS, with PFOS appearing in about half of the samples, but 95% of th…
    STAT · 5mo agoRegulatoryNeutral↗ source
  • AbbVie's Skyrizi sales growth raises investor worries about J&J competition
    During AbbVie's first-quarter earnings call, analysts focused on the company's immunology franchise and asked how it would defend Skyrizi against emerging competition from Johnson & Johnson. The c…
    Endpoints · 5mo agoEarningsNegative↗ source
  • Teva nabs experimental Tourette drug in $700M Emalex buyout
    A Jefferies analyst argued the deal — Teva’s largest in a decade — “makes sense” given the synergies between Emalex and the pharmaceutical giant’s neurology business.
    BioPharma Dive · 5mo agoDealNeutral↗ source
  • FDA urges Amgen to withdraw Tavneos after alleging data manipulation by former developer
    The FDA has sent a formal letter to Amgen recommending that the company pull its drug Tavneos from the market. The agency says new information shows the original approval filings from ChemoCentryx…
    BioPharma Dive · 6mo agoRegulatoryNegative↗ source
  • BridgeBio's heart drug Attruby exceeds sales expectations, shifting investor outlook
    BridgeBio prepared to sell its heart drug Attruby on its own, prompting skepticism from investors and analysts who doubted the company could compete with larger rivals. The drug far outperformed f…
    BioPharma Dive · 6mo agoPositive↗ source
  • FDA commissioner touts real-time trial monitoring to cut drug development dead time
    The Food and Drug Administration announced a new approach that will let regulators view clinical trial endpoints as they happen, using cloud‑based data streams. The move targets the long delays th…
    STAT · 6mo agoRegulatoryPositive↗ source
  • Coultreon secures $125M Series A to advance oral immune drug into Phase 2 trials
    Coultreon Biopharma announced a $125 million Series A financing round to fund development of an oral drug it licensed from Galapagos. The round was led by Sofinnova Investments and included nine i…
    BioPharma Dive · 6mo agoDealPositive↗ source
  • Coultreon Biopharma secures $125M to advance SIK inhibitor for autoimmune diseases
    Coultreon Biopharma announced a $125 million financing round on April 28, 2026, backed by major biotech investors from the United States and Europe. The capital will be used to develop a new appro…
    Endpoints · 6mo agoDealPositive↗ source
  • New hepatitis B vaccine guidance prompts analysis of public trust and policy impacts
    The Morning Rounds newsletter examines how the latest recommendations for a hepatitis B vaccine could affect public health outcomes. It highlights recent surveys that show varying levels of confid…
    STAT · 6mo agoNeutral↗ source
  • New U.S. hepatitis B vaccine policy targeting only at-risk newborns could raise infant infections and costs, studies warn
    A new U.S. recommendation limits the birth‑dose hepatitis B vaccine to infants who are judged to be at risk of neonatal infection, rather than offering it universally to all newborns. One study co…
    STAT · 6mo agoRegulatoryNegative↗ source
  • Eli Lilly to acquire Ajax Therapeutics for up to $2.3 billion to develop improved JAK inhibitor
    Eli Lilly announced Monday it will purchase Ajax Therapeutics, a biotech based in New York and Cambridge, Massachusetts, in a deal valued at up to $2.3 billion. The transaction includes cash up fr…
    BioPharma Dive · 6mo agoDealPositive↗ source
  • Oruka's yearly injectable shows 63% complete clearance in mid-stage psoriasis trial
    Oruka Therapeutics reported results from a Phase 2 trial of its long-acting injectable, ORKA-001, in patients with plaque psoriasis. In the study, 63% of participants achieved complete skin cleara…
    STAT · 6mo agoPositive readoutPositive↗ source
  • GLP-1 drugs and eating disorder risk examined as Covid impact wanes in 2026
    The Morning Rounds newsletter explores the potential link between GLP-1 medications and the development of eating disorders, emphasizing that the risk remains uncertain and warrants further study.…
    STAT · 6mo agoNeutral↗ source
  • Experts say Covid risk has faded, but boosters still advised for vulnerable groups
    Health journalist Helen Branswell reflects on how Covid-19, once the dominant global threat, has receded in public consciousness. Six years after the 2020 lockdowns, mask-wearing and social distanc…
    STAT · 6mo agoNeutral↗ source
  • CDC flu research pioneer Nancy Cox dies at 77
    Nancy Cox, a longtime CDC veteran, passed away at age 77 after battling glioblastoma, a form of brain cancer. Cox led the agency's influenza division for 22 years, expanding the team from a modest…
    STAT · 6mo agoNeutral↗ source
  • New Podcast 'Drug Story' Explores the Cultural Impact of Blockbuster Medications
    The First Opinion team has launched a new podcast called “Drug Story,” hosted by journalist and entrepreneur Thomas Goetz. The series aims to uncover the hidden narratives behind widely used medici…
    STAT · 6mo agoPositive↗ source
  • Endpoints Weekly celebrates Neal Awards while previewing Sanofi, Lilly and RevMed updates
    Endpoints Weekly released its latest edition on April 25, 2026, noting a celebratory tone after the publication earned three Neal Awards for B2B journalism excellence. The issue highlights several…
    Endpoints · 6mo agoPositive↗ source
  • Eli Lilly to acquire cancer cell therapy startup Kelonia Therapeutics for $3.2 billion
    Eli Lilly announced it will buy privately held Kelonia Therapeutics, a biotech focused on cell therapies for cancer and autoimmune diseases, in a deal valued at $3.2 billion. Kelonia has operated…
    STAT · 6mo agoDealPositive↗ source
  • European regulators recommend Sanofi's MS drug tolebrutinib for approval after US rejection
    European Medicines Agency officials issued a positive recommendation for tolebrutinib, an experimental multiple sclerosis therapy from Sanofi, after the U.S. FDA rejected the drug earlier this year…
    BioPharma Dive · 6mo agoRegulatoryPositive↗ source